Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.60 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2951108 | 0.90 | GPR119 (0.63) | GPR119CHEK2ALDH1A1HRH3USP30 | |
| SCHEMBL75936 | 0.87 | GPR119 (0.59) | GPR119CHEK2ALDH1A1HRH3USP30 | |
| SCHEMBL23410126 | 0.86 | GPR119 (0.58) | GPR119CHEK2ALDH1A1HRH3MMP13 | |
| SCHEMBL29981348 | 0.86 | GPR119 (0.58) | GPR119CHEK2ALDH1A1HRH3MMP13 | |
| SCHEMBL5538341 | 0.85 | GPR119 (0.63) | GPR119CHEK2ALDH1A1USP30MMP13 | |
| SCHEMBL3073527 | 0.85 | GPR119 (0.65) | GPR119CHEK2ALDH1A1HRH3USP30 | |
| SCHEMBL74203 | 0.83 | GPR119 (0.67) | GPR119CHEK2ALDH1A1HRH3USP30 | |
| SCHEMBL2735422 | 0.83 | GPR119 (0.67) | GPR119CHEK2ALDH1A1HRH3USP30 | |
| SCHEMBL264162 | 0.83 | GPR119 (0.67) | GPR119CHEK2ALDH1A1HRH3USP30 | |
| SCHEMBL12533230 | 0.83 | GPR119 (0.67) | GPR119CHEK2ALDH1A1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129412-B2 | Hydantoin derivatives useful as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-1828166-B1 | HYDANTOIN DERIVATIVES USEFUL AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | EP | disclosed |
| US-20080280950-A1 | Hydantoin Derivatives Useful as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| EP-1828166-A1 | HYDANTOIN DERIVATIVES USEFUL AS METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006064218-A1 | HYDANTOIN DERIVATIVES USEFUL AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280950-A1 | Hydantoin Derivatives Useful as Metalloproteinase Inhibitors | MMP3, MMP9, MMP2 | GPR119 2077/4885CHEK2 4397/4885ALDH1A1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.